How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pneumonia-due-to-escherichia-coli.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pneumonia due to Escherichia coli — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pneumonia due to Escherichia coli (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumonia due to Escherichia coli, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Teflaro	CEFTAROLINE FOSAMIL	AbbVie	Cephalosporin Antibacterial		2010-01-01
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
AZLOCILLIN	AZLOCILLIN	Bayer Pharmaceuticals Corp	azlocillin		1982-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 13 drugs in Pneumonia due to Escherichia coli
Merck & Co. · 3 drugs in Pneumonia due to Escherichia coli
Pai Holdings Pharm · 2 drugs in Pneumonia due to Escherichia coli
Pfizer · 2 drugs in Pneumonia due to Escherichia coli
Bristol-Myers Squibb · 2 drugs in Pneumonia due to Escherichia coli
Centre Hospitalier Universitaire Vaudois · 1 drug in Pneumonia due to Escherichia coli
GSK · 1 drug in Pneumonia due to Escherichia coli
Generic (originally Roche) · 1 drug in Pneumonia due to Escherichia coli
AbbVie · 1 drug in Pneumonia due to Escherichia coli
Merck Sharp & Dohme B.V. · 1 drug in Pneumonia due to Escherichia coli
Novartis · 1 drug in Pneumonia due to Escherichia coli
Poitiers University Hospital · 1 drug in Pneumonia due to Escherichia coli

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumonia due to Escherichia coli:

Cite this brief

Drug Landscape (2026). Pneumonia due to Escherichia coli — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumonia-due-to-escherichia-coli. Accessed 2026-06-10.

Pneumonia due to Escherichia coli full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing